Original Article
materIals and methods
This series includes 51 patients with acromegaly who visited department of Endocrinology, SKIMS Srinagar, between October 2015 and April 2017. These included: (a) patients first time suspected and proved to have acromegaly (new, prospective patients), and (b) patients with previously diagnosed acromegaly of whatever duration and whether treated or not (old, retrospective patients). Institutional Ethics Committee exempted the study from the ethical clearance as during the meeting it was found that the study involved collection of anonymous data of acromegaly patients.
The records of the retrospective patients were analyzed for clinical characteristics and the results of endocrine and radiological investigations. The prospective patients received a detailed clinical assessment. In addition to routine biochemical investigations, they received glucose suppression test (GST) for growth hormone (GH) using 75 g anhydrous glucose and taking samples for GH at 30, 60, 90, and 120 min. Acromegaly was diagnosed if the nadir plasma GH level during the GST was 1 ng/ml or more; and/or, IGF-1 levels above the upper limit of age matched range. [5] In the case of patients with uncontrolled diabetes mellitus, this test was undertaken after achieving glycemic control for 2 weeks. [6] In addition to the routine preoperative biochemical investigations, hormone profile including 8 AM serum cortisol, T3, T4, thyroid stimulating hormone (TSH), luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone and prolactin, including GH were measured. All were measured by DXI 800, Beckman Coulter Chemiluminescence random access analyzer following manufacturer's protocol.
A gadolinium enhanced magnetic resonance imaging (MRI) of the hypothalamopituitary area was obtained in all new acromegaly patients and was interpreted by a single experienced radiologist. For the retrospective patients, all the available pre-and post-treatment MRI and CT films were reviewed.
The post treatment assessment was performed at 3 months to assess the results of treatment. This included clinical assessment, endocrine evaluation of pituitary functions as indicated, and MRI of the hypothalamopituitary area. Random GH followed by glucose suppression test for nadir GH values was performed at 3 months.
Statistical analysis
Statistical Package for Social Sciences, SPSS 22, was used for data analysis. The results were expressed as percentages or mean ± SD, as specified. Pearson's Chi-square method was used for comparing proportions and percentages whereas Student's t-test was used for comparison of continuous variables. A two-tailed P value was used for calculating statistical significance; a value of <0.05 was taken as significant.
results
The series included 51 (28 prospective and 23 retrospective) patients, with the mean age at presentation being 42.3 ± 10.87 years (range 22--70 years). The mean height of the whole group was 167.3 ± 8.2 cms with a range of 152--187 cm. The average body mass index (BMI) was 27.0 kg/m 2 . Imaging revealed a pituitary microadenoma in 10 and pituitary macroadenoma in 39 patients.
Clinical features
Our patients had a broad spectrum of presenting manifestations, ranging from acral enlargement, headache to musculoskeletal manifestations, and even diabetes mellitus. Overall, the three most common presentations were acral enlargement followed by headache and facial coarsening. All the clinical features encountered have been listed in Figure 1 . Hypertension was present in 45.1% and diabetes mellitus in over a fifth (21.6%) of patients. One third of the females had menstrual disturbances.
Investigations
About a half (22/51) of our patients had glucose intolerance, including six, five, and eleven patients with impaired glucose tolerance, impaired fasting, and diabetes mellitus, respectively. Dyslipidemia was seen in more than two-thirds of our patients with elevated total cholesterol (>200 mg/dl) in 35.14% and triglycerides (>150 mg/dl) in 67.5%. Over a quarter of patients had evidence of ventricular hypertrophy, one-fifth had visceromegaly and two patients had colonic polyps [ Table 1 ].
Pretreatment hormonal profile
Pretreatment growth hormone (GH) values at various intervals after a glucose load (75 g) revealed average GH levels at 30, 60, 90, and 120 min were 21.72 ± 12.83, 21.74 ± 12.92, 20.98 ± 11.85, and 19.27 ± 12.37 ng/ml, respectively. All the six patients who had a preoperative IGF-1 estimation had clearly elevated levels. Gonadotropin deficiency was the commonest associated pituitary deficit [ Table 2 ]. Preoperatively only one patient with micro-adenoma had hypocortisolism, which was persistent in postoperative period, while no patient had pre-or postoperative hypothyroidism or hypogonadism. 
Treatment modalities used
An overwhelming majority (88.2%) of the patients received surgery as primary modality of treatment; the approach was transnasal trans-sphenoidal in 93% and subfrontal in 7%. Three (5.9%) patients received primary medical therapy while three others declined any treatment.
Post-treatment Hormone Profile and Imaging
Postoperatively, mean GH levels at 30, 60, 90, and 120 min after glucose load were 5.44 ± 8.72, 5.29 ± 8.43, 4.07 ± 6.18, and 4.64 ± 6.88 ng/ml, respectively. Postoperatively, the nadir GH following a glucose load was <1 ng/ml in 10 (27.3%), 1 to <2.5 ng/ml in 11 (29.73%), 2.5 to <5 ng/ml in 8 (21.62%), 5 to <10 ng/ml in 4 (10.81%), and 10 to 20 ng/ml in 4 (10.81%) of the 37 patients on whom the information was available.
Post-treatment, hypogonadism continued to be the most common pituitary hormone deficiency [ Table 2 ]. As per the present consensus criteria, 23.7% patients achieved disease control (40% with microadenoma and only 19.5% with macroadenoma).
Postoperative MRI performed at variable periods (2--7 months) after treatment was available in 43 patients and revealed residual/recurrent disease in 24 (55.8%). Of the 24 patients with residual/recurrent disease, 12 (50%) were started on medical therapy (monthly octreotide depot preparation in 5 and cabergoline in 7 patients), while six (25%) were treated with repeat surgery and six patients received radiotherapy.
Complications
The surgical complications occurred in five (11.6%) of our operated patients and included postoperative CSF leak in three (6.96%) and postoperative meningitis in two (4.6%). All of these, except one, were having macroadenoma.
dIscussIon
This is a sizeable series evaluating the clinical presentations and outcome of acromegalic patients and has afforded a glimpse of the state of overall care of these patients from the Indian subcontinent. The mean age at presentation was Table 3 ]. The mean height at presentation was 167.3 ± 8.19 cm (the average Indian standard height being 157.5 cm), with BMI of 27 ± 3.24 kg/m 2 consistent with previous studies. [6] [7] [8] Earlier literature from national series as well as the registries from Spain and Belgium reported similar findings. [9, 10] Patients with acromegaly present with a wide spectrum of manifestations. In our series, the most common presenting manifestations were acral enlargement (90%) and headache (71%). Reid et al. reported headache at diagnosis in nearly half of the 324 patients with acromegaly. [11] In our study, the prevalence of headache was significantly lower in the prospectively studied 28 patients than in the retrospectively studied 23 patients (52.2 vs. 85.7%; p 0.008). We believe this to be due, at least partly, to relatively earlier diagnosis in the prospectively studied patients. Table 3 compares the characteristics of our patients with that reported from PGI Chandigarh, CMC Vellore, and Belgian Registry. The prevalence of hypertension in acromegaly is variable, ranging from 18% to 60%. [13] Hypertension (45.1%) in our patients was more as compared with the overall prevalence of 29.8% in the Indian population. Hypertension is believed to contribute to the impaired cardiovascular function in acromegaly. [14] Hypertention, diabetes mellitus, and arthropathy incidence is similar, except from the series of PGI Chandigarh where it is lower, which could be due to abundance of younger patients in their series.
Sleep apnea were reported by 13.7% of our patients according to STOP BANG criteria. We did not perform sleep studies in our patients and this fact explains the low prevalence of sleep apnea in our patients as compared with other studies which reported a prevalence between 39 and 79%. [8, 11] In keeping with the increased incidence of micronephrolithiasis with acromegaly and its significant correlation with disease duration, four (7.6%) of our patients had renal stone disease. [15] Sixty five percent patients had deficiency of one or more anterior pituitary hormones (in whom hormone profile was available), which was less than reported by Dutta et al. but more as compared with 39.7% from the Belgian acromegaly registry. [6, 9] Hypogonadism was the most common hormone deficiency in our series which was different from reported by others. The remission rates in our study was less as compared with rest [ Table 3 ] as well as to other reports that ranged from 57.3% to 64% when surgeries were performed by a single dedicated pituitary surgeon. [16, 17] The cure and control in acromegaly is largely a function of the skill and experience of the operating surgeon.
The postoperative MRI done at least 3 months after surgery revealed residual disease in 55.8% of our patients. Abe reported residual disease in 40%. [18] Usually effective medical agents are used very infrequently in our patients with acromegaly. The main reason for this is poor affordability of our patients; inconsistent availability and accessibility to such medications also contribute.
Postoperative complications are reported in about 11% of patients and their incidence again depends on the experience of the operating surgeon. The lower figure in our study likely reflects inconsistency in documentation of seemingly innocuous events and inherent difficulties in "post-event" data collection.
Some of the limitations of our study include its retrospective cum prospective nature, relatively small number of patients, incomplete hormone profile, and heterogeneity of data given that some patients had evaluation at more than one place.
conclusIons
Acromegaly is a disabling but potentially curable disease. Our patients presented with an advanced and aggressive disease, and higher GH levels. The higher mean growth hormone levels in our series was likely due to late detection of the disease. The majority of them harbored a macroadenoma and had lower cure rates, due to lack of a dedicated pituitary surgeon. In a resource constrained nation like ours, it would be cost-effective to develop a dedicated surgical team focused on management of pituitary disorders, as administration of a prolonged medical therapy in the event of treatment failure is often unaffordable.
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